$1.46
−2.01%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.46
From 52W high−65.65%
Volume43914.00
Market cap$10.78M
P/E (TTM)—
P/S (TTM)792.7x
Div yield—
Key dataSep 18, 2026
Open
$1.46
From 52W high
−65.65%
Volume
43914.00
Market cap
$10.78M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.6x
P/E (TTM)
—
RSI (14)
46.5
MomentumView details →
1D Return
−2.01%
YTD Return
−13.72%
SummaryUpdated Jun 1, 2026
Ainos, Inc. (NASDAQ:AIMD) is a biotechnology company founded in 1984 and headquartered in San Diego, California. Originally incorporated as Amarillo Biosciences, Inc., the company rebranded to Ainos in May 2021 and went public through an IPO in January 2021. The company operates in the healthcare sector, focusing on developing medical technologies for point-of-care diagnostic testing and novel therapeutic treatments for various disease indications.
Similar companies
Latest newsMore news →
Ainos, Inc.'s proprietary real-world chemical dataset surpassed 1 billion records.4d agoAinos announced that its second-generation AI Nose has entered commercial deployment at semiconductor fabs for front-end manufacturing chemical sensing.5d agoAinos, Inc. announced that its second-generation AI Nose platform is advancing into commercial deployment in front-end semiconductor manufacturing, with initial commercial orders received from a front-end semiconductor company.6d ago